Media and Communications

News

2007 News Releases

Monday, December 24, 2007
Teva Announces Launch of Generic Protonix® Tablets, 20 Mg and 40 Mg Company Increases 2007 EPS Guidance to Between $2.34 and $2.36 Company to Hold Conference Call at 8:45 A.M. Eastern Time

Jerusalem, Israel, December 24, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that it has commercially launched Pantoprazole Sodium Delayed Release (DR) Tablets, 20 mg and 40 mg, which are AB-rated to Wyeth's erosive GERD treatment Protonix® DR Tablets. The brand product had annual sales of approximately $2.5 billion in the United States for the twelve months ended September 30, 2007, based on IMS sales data.As one of the first companies to file an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for this product, Teva has been awarded Read More »

Wednesday, December 12, 2007
Teva Announces Approval Of Generic Trileptal® Tablets

Jerusalem, Israel, December 12, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' antiepileptic therapy Trileptal® (Oxcarbazepine) Tablets, 150 mg, 300 mg and 600 mg. Shipment of the product will begin in the near future.The brand product had annual sales of approximately $690 million in the United States for the twelve months ended September 30, 2007, based on IMS sales data.Teva is currently involved Read More »

Monday, December 03, 2007
Early Treatment with COPAXONE® Demonstrated Robust Protection against Progression to Clinically Definite Multiple Sclerosis in the PreCISe Study

Efficacy Is Attained and the Study Is Stopped after Interim Analysis and Supports Filing of COPAXONE® For Patients with a First Clinical Event Suggestive of MS Jerusalem, Israel, December 3, 2007 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced the positive results from a pre planned interim analysis of the PreCISe trial in patients presenting with a first clinical event and MRI features suggestive of multiple sclerosis (MS). The results showed that treatment with COPAXONE® (glatiramer acetate injection) reduced the risk of developing clinically definite MS (CDMS) by 44 pe Read More »

Friday, November 30, 2007
Teva Announces Tentative Approval Of Generic Requip® Tablets

Jerusalem, Israel, November 30, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of GlaxoSmithKline's Requip® (Ropinirole HCl) Tablets, Eq. 0.25 mg base, 0.5 mg base, 1 mg base, 2 mg base, 3 mg base, 4 mg base and 5 mg base. Final approval of Teva's Ropinirole HCl Tablets is expected upon expiry of patent protection for the brand product on May 19, 2008. Upon final approval, Teva's product will be the AB- Read More »

Wednesday, November 07, 2007
Initiation Of Enrollment In Pivotal Phase III Clinical Study Of Oral Laquinimod For Relapsing-Remitting Multiple Sclerosis

Jerusalem, Israel and Lund, Sweden, November 7, 2007 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB (OMX NORDIC: ACTI) announced today the initiation of enrollment in the Allegro trial (assessment of oral laquinimod in preventing progression of multiple sclerosis). Allegro is a global pivotal, 24/30-month, double-blind, Phase III study designed to evaluate the efficacy, safety and tolerability of the oral investigational compound laquinimod versus placebo in the treatment of relapsing-remitting multiple sclerosis (RRMS). The Allegro trial aims to enroll approximatel Read More »

Tuesday, November 06, 2007
First Patient Undergoes Expanded Cord Blood Transplant in the ExCell Registration Study of StemEx® for Leukemia and Lymphoma

Patients are now being enrolled in the U.S. for the Gamida Cell-Teva Joint Venture ExCell trial studying StemEx® as an alternative treatment for bone marrow transplants. Jerusalem, Israel, November 6, 2007 - Gamida Cell-Teva Joint Venture announced today that the first patient in the international, pivotal registration ExCell study has undergone a StemEx® transplant at the Ireland Cancer Center of University Hospitals Case Medical Center. StemEx® is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded c Read More »

Tuesday, October 30, 2007
Teva Announces Planned Retirement Of CFO Dan Suesskind In Mid-2008

Company Appoints Check Point CFO And Former Teva Deputy Cfo, Eyal Desheh, As Successor Jerusalem, Israel, October 30, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that Chief Financial Officer Dan Suesskind plans to retire in mid-2008. Eyal Desheh, currently Executive Vice President and Chief Financial Officer of Check Point Software Technologies (Nasdaq: CHKP) has been appointed to succeed Mr. Suesskind as Teva's CFO.Eli Hurvitz, Chairman of the Board of Directors at Teva, said, "Since Dan was appointed CFO in 1977, he has played a pivotal role in all of Teva Read More »

Tuesday, October 30, 2007
Teva Reports Third Quarter 2007 Results

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced its financial results for the third quarter ended September 30, 2007. Jerusalem, Israel, October 30, 2007 - Third Quarter Highlights*Net sales of $2,366 million, up 4 percent over the third quarter of 2006 - a quarter that included three of the industry's largest marketing exclusivities. *Net income of $525 million compared to $606 million in the comparable quarter of 2006. *Diluted EPS of $0.64 compared to diluted EPS of $0.74 in the prior year quarter.*Record-breaking global in-market sales for Copaxone® of $441 million; up Read More »

Tuesday, October 23, 2007
Copaxone® Significantly Decreases Disease Activity In Patients Who Switched From Interferon Beta (Ifnb) Due To Development Of Neutralizing Antibodies (Nabs)

Relapsing-remitting multiple sclerosis Patients Experience Significantly Extended Time to First Relapse Compared to NAbs-Positive IFNb Patients Jerusalem, Israel, October 23, 2007 - Patients treated with interferon beta (IFNb) who have experienced loss of efficacy due to the development of neutralizing antibodies, had a significant delay in time to first relapse (p=0.0389) following switch to COPAXONE®. In addition, patients who were switched to COPAXONE® experienced reduction in mean annual relapse rate compared to Pre IFNb treatment. Results from this retrospective comparative study were pr Read More »

Monday, October 22, 2007
Adenoscan® Patent Lawsuits Settled

Astellas, King and Item finalize settlement agreement with TevaTokyo, Japan/Bristol, TN, USA/Jerusalem, Israel, October 22, 2007 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Masafumi Nogimori), King Pharmaceuticals, Inc. ("King"; NYSE: KG) and Teva Pharmaceutical Industries Ltd. ("Teva" Nasdaq:TEVA) today announced that US subsidiaries of Astellas, along with Item Development AB ("Item") and King have executed settlement agreements with one of Teva's subsidiaries on lawsuits filed in the United States against Teva's subsidi Read More »

​​​